Article Sidebar

pdf
Date Published: 29/10/2025
Abstract Views: 116
Views pdf: 67
DOI: https://doi.org/10.51298/vmj.v555i1.15878
Issue
Vol. 555 No. 1 (2025)
Section
Các bài báo
How to Cite
Bùi, T. Đạt, Nguyễn, T. T. H., Nguyễn, T. T. H., & Trịnh , L. H. (2025). EFFICACY AND ADVERSE EFFECTS OF ATEZOLIZUMAB AS SECOND-LINE TREATMENT IN STAGE IV NON-SMALL CELL LUNG CANCER. Vietnam Medical Journal, 555(1). https://doi.org/10.51298/vmj.v555i1.15878

EFFICACY AND ADVERSE EFFECTS OF ATEZOLIZUMAB AS SECOND-LINE TREATMENT IN STAGE IV NON-SMALL CELL LUNG CANCER

Tiến Đạt Bùi, Thị Thái Hoà Nguyễn, Thị Thu Hường Nguyễn, Lê Huy Trịnh

Main Article Content

Abstract

CELL LUNG CANCER


Objective: This study aimed to evaluate the response rate and adverse effects of Atezolizumab as a second-line treatment in patients with stage IV non-small cell lung cancer (NSCLC). Methods: A retrospective descriptive study was conducted on 59 patients with stage IV NSCLC who had previously failed platinum-based doublet chemotherapy. These patients received second-line treatment with Atezolizumab at K Hospital from November 2020 to May 2025. The study assessed treatment response rates and treatment-related adverse events. Results: The objective response rate (ORR) was 17%, and the disease control rate (DCR) was 45.8%. Disease progression occurred in 54.2% of patients. Most adverse events were grade 1–2, including elevated liver enzymes (18.6%), fatigue (18.7%), and nausea (8.5%). No grade 3–4 adverse events were recorded, except for one case of grade 3 fatigue (1.7%). Conclusion: Second-line monotherapy with Atezolizumab demonstrated promising efficacy and safety in patients with stage IV NSCLC who had failed prior chemotherapy. The treatment was particularly effective in patients with good performance status (PS 0–1).

Article Details

Keywords

Non-small cell lung cancer, Stage IV, Atezolizumab, Second-line treatment, Treatment efficacy, Adverse events.

References

Zhou, J., Xu, Y., Liu, J., Feng, L., Yu, J., & Chen, D. (2024). Global burden of lung cancer in 2022 and projections to 2050: Incidence and mortality estimates from GLOBOCAN. Cancer Epidemiol, 93, 102693. https://doi.org/10.1016/j.canep.2024.102693
2. Cancer, I. A. f. R. o. (2024, February 8, 2024). Viet Nam - Statistics at a glance, 2022. Global Cancer Observatory. Retrieved June 22 from https://gco.iarc.who.int/media/globocan/factsheets/populations/704-viet-nam-fact-sheet.pdf
3. Schiller, J. H., Harrington, D., Belani, C. P., Langer, C., Sandler, A., Krook, J., Zhu, J., & Johnson, D. H. (2002). Comparison of four chemotherapy regimens for advanced non-small-cell lung cancer. N Engl J Med, 346(2), 92-98. https://doi.org/10.1056/NEJMoa011954
4. Rittmeyer, A., Barlesi, F., Waterkamp, D., Park, K., Ciardiello, F., von Pawel, J., Gadgeel, S. M., Hida, T., Kowalski, D. M., Dols, M. C., Cortinovis, D. L., Leach, J., Polikoff, J., Barrios, C., Kabbinavar, F., Frontera, O. A., De Marinis, F., Turna, H., Lee, J. S.,… Gandara, D. R. (2017). Atezolizumab versus docetaxel in patients with previously treated non-small-cell lung cancer (OAK): a phase 3, open-label, multicentre randomised controlled trial. Lancet, 389(10066), 255-265. https://doi.org/10.1016/s0140-6736(16) 32517-x
5. Eisenhauer, E. A., Therasse, P., Bogaerts, J., Schwartz, L. H., Sargent, D., Ford, R., Dancey, J., Arbuck, S., Gwyther, S., Mooney, M., Rubinstein, L., Shankar, L., Dodd, L., Kaplan, R., Lacombe, D., & Verweij, J. (2009). New response evaluation criteria in solid tumours: revised RECIST guideline (version 1.1). Eur J Cancer, 45(2), 228-247. https://doi.org/10.1016/j.ejca.2008.10.026
6. Fehrenbacher, L., Spira, A., Ballinger, M., Kowanetz, M., Vansteenkiste, J., Mazieres, J., Park, K., Smith, D., Artal-Cortes, A., Lewanski, C., Braiteh, F., Waterkamp, D., He, P., Zou, W., Chen, D. S., Yi, J., Sandler, A., & Rittmeyer, A. (2016). Atezolizumab versus docetaxel for patients with previously treated non-small-cell lung cancer (POPLAR): a multicentre, open-label, phase 2 randomised controlled trial. Lancet, 387(10030), 1837-1846. https://doi.org/10.1016/s0140-6736(16)00587-0
7. Socinski, M. A., Nishio, M., Jotte, R. M., Cappuzzo, F., Orlandi, F., Stroyakovskiy, D., Nogami, N., Rodríguez-Abreu, D., Moro-Sibilot, D., Thomas, C. A., Barlesi, F., Finley, G., Kong, S., Lee, A., Coleman, S., Zou, W., McCleland, M., Shankar, G., & Reck, M. (2021). IMpower150 Final Overall Survival Analyses for Atezolizumab Plus Bevacizumab and Chemotherapy in First-Line Metastatic Nonsquamous NSCLC. J Thorac Oncol, 16(11), 1909-1924. https://doi.org/10.1016/j.jtho.2021. 07.009
8. Lê Huy Thắng, & Phạm Văn Thái. (2022). Kết quả điều trị bước sau ung thư phổi không tế bào nhỏ giai đoạn di căn xa bằng phác đồ atezolizumab đơn trị. Tạp chí Y học Việt Nam, 518(1). https://doi.org/10.51298/vmj.v518i1.3375